Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 17/20 | 1.00 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.81 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.70 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18613706 | 1.00 | FYN (1.00) | FYNCHEK2TGFBR1CHEK1 | |
| SCHEMBL30521680 | 0.87 | FYN (1.00) | FYNCHEK2TGFBR1 | |
| SCHEMBL4622006 | 0.87 | FYN (1.00) | FYNCHEK2TGFBR1 | |
| SCHEMBL12518226 | 0.87 | FYN (1.00) | FYNCHEK2TGFBR1CHEK1 | |
| SCHEMBL18613689 | 0.85 | FYN (1.00) | FYNCHEK2TGFBR1CHEK1 | |
| SCHEMBL18613263 | 0.85 | FYN (1.00) | FYNCHEK2TGFBR1 | |
| SCHEMBL18613248 | 0.85 | FYN (1.00) | FYNCHEK2TGFBR1CHEK1 | |
| SCHEMBL18860392 | 0.84 | TGFBR1 (0.81) | FYNCHEK2TGFBR1CHEK1 | |
| SCHEMBL2226987 | 0.84 | FYN (0.75) | FYNCHEK2TGFBR1CHEK1 | |
| SCHEMBL18613284 | 0.84 | FYN (1.00) | FYNCHEK2TGFBR1CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240041868-A1 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors | Pathways Neuro Pharma, Inc. | 2024-02-08 | — | — | US | disclosed |
| US-11701353-B2 | Methods, compositions, and uses of novel FYN kinase inhibitors | Pathways Neuro Pharma, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240041868-A1 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors | FYN, LCK, PTK2B | FYN 1/4885CHEK2 363/4885TGFBR1 3710/4885 |
| US-11701353-B2 | Methods, compositions, and uses of novel FYN kinase inhibitors | FYN, LCK, PTK2B | FYN 1/4885CHEK2 363/4885TGFBR1 3710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.